^
    2ms
    ACTM-838-01: A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=10, Terminated, Actym Therapeutics, Inc. | N=35 --> 10 | Trial completion date: Jul 2026 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Aug 2025; Sponsor's strategic business decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ACTM-838
    2ms
    ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response. (PubMed, Oncotarget)
    Single-cell RNAseq and flow cytometry data confirmed activation and infiltration of both innate and adaptive immune cells. ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in combination.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1) • TGFB1 (Transforming Growth Factor Beta 1) • IFNA1 (Interferon Alpha 1) • IL15 (Interleukin 15)
    |
    ACTM-838
    over1year
    ACTM-838-01: A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=35, Recruiting, Actym Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    ACTM-838
    over1year
    A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Actym Therapeutics, Inc.
    New P1 trial • Metastases
    |
    ACTM-838
    over2years
    ACTM-838, a novel immunotherapy that enriches in solid tumors after IV dosing and comprehensively reverses the immunosuppressive TME to promote durable anti-tumor immunity (AACR 2023)
    Analyses of public RNAseq datasets from patients with primary or metastatic disease revealed cancer types with high levels of myeloid infiltration and adenosine enrichment, suggesting that ACTM-838 efficacy could provide benefit in these indications.ACTM-838 is a novel immunotherapy delivering IL-15plex + eSTING payloads to phagocytic APCs, inducing a durable anti-tumor immune response, after IV dosing. It possesses a compelling safety profile, and is currently in IND-enabling, preclinical development.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • STING (stimulator of interferon response cGAMP interactor 1) • IL15 (Interleukin 15)
    |
    ACTM-838